Under the determination, which will become final following publication in Germany's Federal Gazette, Oncotype DX becomes the only multigene test nationally reimbursed in Germany for its target population early-stage breast cancer patients.
The diagnostic will now be a contracted service with Anthem Blue Cross of California and 10 of its affiliated health plans.
As of July 1, the Guardant360 test will be considered medically necessary for aiding therapy selection in advanced lung cancer for health plan members of EviCore.
NantHealth CEO Patrick Soon-Shiong said that the company is seeking a fast-track FDA clearance predicated on Memorial Sloan Kettering's 468-gene panel.
Under a proposed decision, to be finalized in August and become effective in late 2020, NIPT would only be covered for women with particular fetal trisomy risks.
While a number of hospitals have sold their outreach operations in recent years, observers suggest these businesses are well-suited to the current environment.
Lab director Glenn George discusses trends within clinical microbiology that could set it apart from other portions of the clinical laboratory.
City of Hope and Texas Oncology are the first customers for Trapelo, a decision support platform from Innovation Insights that involves labs and payors.
The non-coverage decision came despite appeals by the company following a draft non-coverage determination issued last year.
In a pair of recent studies, Crescendo put forth new clinical utility data and an age and adiposity-adjusted model for its Vectra DA rheumatoid arthritis test.